Tau-focused immunotherapy for Alzheimer's disease and related tauopathies. - Wikidata - thesis-toulmin - TriplyDB

Tau-focused immunotherapy for Alzheimer's disease and related tauopathies.

Tau-focused immunotherapy for Alzheimer's disease and related tauopathies.

http://www.wikidata.org/entity/Q37623855

about

Alzheimer mechanisms and therapeutic strategies Advances in Alzheimer's disease drug development Tau-targeted treatment strategies in Alzheimer's disease The zinc dyshomeostasis hypothesis of Alzheimer's disease Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease Phenothiazine-mediated rescue of cognition in tau transgenic mice requires neuroprotection and reduced soluble tau burden.Combined immunotherapy with "anti-insulin resistance" therapy as a novel therapeutic strategy against neurodegenerative diseases.Oligomeric tau-targeted immunotherapy in Tg4510 mice.Disruption of odour quality coding in piriform cortex mediates olfactory deficits in Alzheimer's disease Epitope analysis following active immunization with tau proteins reveals immunogens implicated in tau pathogenesis.In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice.A dual vaccine against influenza & Alzheimer's disease failed to enhance anti-β-amyloid antibody responses in mice with pre-existing virus specific memory.Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model In vitro aggregation assays using hyperphosphorylated tau protein.The many faces of tau Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain.Tau-Directed Immunotherapy: A Promising Strategy for Treating Alzheimer's Disease and Other Tauopathies.Thinking laterally about neurodegenerative proteinopathies.FTD and ALS: a tale of two diseases Two novel Tau antibodies targeting the 396/404 region are primarily taken up by neurons and reduce Tau protein pathology Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models.Vaccination as a therapeutic approach to Alzheimer's disease.Murine models of Alzheimer's disease and their use in developing immunotherapies.The role of tau in Alzheimer's disease and related disorders.Antibody-based therapy in Alzheimer's disease.Therapeutic applications of antibodies in non-infectious neurodegenerative diseases Tau as a therapeutic target for Alzheimer's disease Immunotherapy for tauopathies.Exosomes: vesicular carriers for intercellular communication in neurodegenerative disorders.Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins.Plant-based vaccines for Alzheimer's disease: an overview.Harnessing the immune system for treatment and detection of tau pathology.Anti-amyloid beta to tau - based immunization: Developments in immunotherapy for Alzheimer disease.Mechanistic Studies of Antibody-Mediated Clearance of Tau Aggregates Using an ex vivo Brain Slice Model.T-cell epitope-dependent immune response in inbred (C57BL/6J, SJL/J, and C3H/HeN) and transgenic P301S and Tg2576 mice.Tau pathology: predictive diagnostics, targeted preventive and personalized medicine and application of advanced research in medical practice.Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo.Souvenaid®: a new approach to management of early Alzheimer's disease.Insight into the Dissociation of Behavior from Histology in Synucleinopathies and in Related Neurodegenerative Diseases.Overview of immunotherapy in Alzheimer's disease (AD) and mechanisms of IVIG neuroprotection in preclinical models of AD.

P2860

Q22252311-1C1BBED2-3CAF-4098-8C0D-0B66551016E9 Q26849352-0C1C4ABD-52A1-48FF-BEF2-2C9A32FF6440 Q27023429-4D7FB5EE-BB1F-447E-B86C-1561BEB3E551 Q28730954-13759290-DCE1-4794-8EE1-EA7C966B3818 Q28740551-5A053B90-D271-49E4-9335-07BFE9EE6CB3 Q30497435-C01D9815-2F64-453F-A5BA-4A549AC0FEBB Q33731321-484CACFC-32F6-471D-91E8-69D1A84FF76A Q33846761-538112DF-0509-4A04-9805-9BAEF83C5313 Q34169501-31EE3895-6470-44F4-A65B-39D871DA2A64 Q34205027-436E8EFD-6AC0-4AD1-89C8-542E4CEFEA32 Q34985153-647E1BE3-9928-4869-935B-929BAC97F057 Q35040016-30C794E1-9A26-4BB4-9B07-89F1006334F4 Q35104249-5E647F98-23E1-4CAF-92A6-1900E8C0D0E7 Q35161820-1B52E334-A214-4886-BD19-C28BB2844DA8 Q35870359-7DD49FA0-9382-42E4-95D5-55AE41EF9118 Q36005623-6B138022-E1C9-45B8-B009-0A09B2B1DCC2 Q36558485-E9582237-A66D-4FB3-A6F2-DFAED40983A9 Q36793466-71F88DC8-C3CC-4C19-95CB-A34E8703F47F Q37241079-9AFDB0C1-59AB-48BE-A1DC-5B4EF4D07E9A Q37311364-D98488FF-F974-4D51-96D2-9F8F7136B68C Q37655247-869F81AA-B3F0-448E-9353-B0DCD4F9F4DF Q37681432-BF0DB63F-B882-4D95-87E0-63A7CF9AD7B1 Q37752915-02561CD6-988A-46E1-9AF3-9AB56B12A26E Q37765632-F7E4C2F3-A4C2-41EA-9770-F98F19337AE9 Q37831912-17BB42DC-9A56-4048-B3C4-09D4EE2DADD2 Q37862785-410A8D53-718C-4559-9E35-7B11E88EEDE4 Q37890451-42EE97FB-F40E-4296-8F43-714542907851 Q37899064-467B15E8-20E7-4326-B333-63C0CEAD52E6 Q38011636-419E39BD-9420-41CF-9CFE-B97BCC5F8F19 Q38122150-4D57DB28-F3E7-4D03-BA42-4F4C652BDA09 Q38176962-2615DAB8-0C4A-4423-ABEC-3B46973065A2 Q38194049-8D2BE538-0493-4848-947B-20A9CC8274E3 Q38219981-6AFF4ABB-ED51-4BE2-958A-538CEC04D110 Q38773662-BD699E90-501B-4FB3-B0B2-49B9CA9A6056 Q39409037-267B7218-CE4A-4688-9E69-AAA26BA4CD72 Q41945501-48C9CEC4-2183-4E50-AFAF-3A75C6749ED8 Q41955482-A2C97F3B-2DA7-4ECA-921C-830D3E92FD2E Q43864462-3CD11048-9C02-4A6A-BE9C-1986B8C3B55F Q46571207-C453F7A9-628C-4AD7-A0DF-84A2E71D607C Q48585657-6CE76256-2988-49E6-A68C-4A6757CED6F2

P2860

Tau-focused immunotherapy for Alzheimer's disease and related tauopathies.

http://www.wikidata.org/entity/Q37623855

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on October 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Tau-focused immunotherapy for Alzheimer's disease and related tauopathies.

@en

Tau-focused immunotherapy for Alzheimer's disease and related tauopathies.

@nl

type

label

Tau-focused immunotherapy for Alzheimer's disease and related tauopathies.

@en

Tau-focused immunotherapy for Alzheimer's disease and related tauopathies.

@nl

prefLabel

Tau-focused immunotherapy for Alzheimer's disease and related tauopathies.

@en

Tau-focused immunotherapy for Alzheimer's disease and related tauopathies.

@nl

P1433

Q37623855-1ECDD39F-8273-463C-BF17-75FA3A0C1033

P1476

Q37623855-9E1F13BD-5AEC-44B5-BC5C-4385953D3894

P2093

Q37623855-FEA01A79-F07B-4567-8D0B-8CE453004462

P2860

Q37623855-0F5D87BA-69E2-4F73-97D0-0CF596B2F2F8

Q37623855-100AA774-23B1-494F-AFCC-CA3D762A5848

Q37623855-11BB1665-5563-40DE-BF25-689AFF19E747

Q37623855-14F8CDC0-7626-45EE-BA6C-7622120A4426

Q37623855-247D2F3E-92C5-4F3F-A4C9-DC0A93F2B8CC

Q37623855-297779D5-E6BE-4C02-A0C4-374278B6AD06

Q37623855-34E2B6ED-C367-431F-BC43-48EEA3503427

Q37623855-3D6B1075-FBE2-49E5-BE0F-97206E541447

Q37623855-415DB69F-B965-4EE8-AEE1-9E1E1CD4E84C

Q37623855-4252A990-8147-4049-8C74-C979933F4B15

P304

Q37623855-3F30090A-4FB7-434D-B38F-68E422DE6F4A

P31

Q37623855-FB671237-71CA-40CA-8AB1-5F29FF3E29E9

P356

Q37623855-4EB314FC-FD28-4095-A6BE-35C4DEAB0853

P433

Q37623855-D7FCBAB4-B351-4CA3-AA8E-8E1586BB9B3F

P478

Q37623855-78489253-4662-4BAA-ACA1-357809C4D798

P50

Q37623855-EC8894B6-109A-4528-942A-777147C41D5C

P577

Q37623855-E4A9C77A-7D9C-4144-B942-D43F4B4AE430

P5875

Q37623855-3A2E309A-6698-4DF8-90DC-E5B1FB4A1751

P698

Q37623855-105C5AB6-B1A5-44E8-854B-62C45D392EB0

P921

Q37623855-2D5184C6-F744-491A-8AD9-5EFEE4E20462

Q37623855-8AF68436-51FD-4282-9262-1D808A9727DA

P932

Q37623855-60A86C5B-EFAD-46E2-B134-B2BAF17C76C4

P356

156720509789207930

P1433

Current Alzheimer Research

P1476

Tau-focused immunotherapy for Alzheimer's disease and related tauopathies

@en

P2093

Einar M Sigurdsson

http://www.w3.org/2001/XMLSchema#string

P2860

Active and passive immunotherapy for neurodegenerative disorders

Extracellular tau promotes intracellular calcium increase through M1 and M3 muscarinic receptors in neuronal cells

Sorting, recognition and activation of the misfolded protein degradation pathways through macroautophagy and the proteasome

Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment

Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease

Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model

Inhibition of amyloid precursor protein processing by beta-secretase through site-directed antibodies.

Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial.

Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial.

Mutant fibrinogen cleared from the endoplasmic reticulum via endoplasmic reticulum-associated protein degradation and autophagy: an explanation for liver disease.

P304

446-450

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2174/156720509789207930

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Einar M Sigurdsson

P577

2009-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

38052784

http://www.w3.org/2001/XMLSchema#string

P698

19874269

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

2891148

http://www.w3.org/2001/XMLSchema#string